

Annex E

EP 856 – Amendment A

1. A liposome within which RNA encoding an immunogen of interest is encapsulated, wherein the liposome comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is between 1kDa and 3kDa; wherein the immunogen elicits an immune response against a coronavirus, and wherein the immunogen is a coronavirus spike polypeptide, wherein the liposome comprises a lipid with a cationic head group and a lipid with a zwitterionic head group, and wherein the liposome is formed from a mixture of lipids, wherein the proportion of those lipids which are PEGylated is less than 10 mol% of the total amount of lipids, and wherein the remainder is made of 35-50 mol% cholesterol, 30-70 mol% cationic lipid and 5-15 mol% DSPC.

~~4. The liposome of any preceding claim, wherein the liposome comprises a lipid with a cationic head group.~~

~~5. The liposome of any preceding claim, wherein the liposome comprises a lipid with a zwitterionic head group.~~

9. A process for preparing a RNA-containing liposome, comprising a step of mixing RNA with one or more lipids, under conditions such that the lipids form a liposome in which the RNA is encapsulated, wherein at least one lipid includes a polyethylene glycol moiety which becomes located on the liposome's exterior during the process, and wherein the average molecular mass of the polyethylene glycol is between 1kDa and 3kDa; wherein the RNA encodes an immunogen which elicits an immune response against a coronavirus, and wherein the immunogen is a coronavirus spike polypeptide, wherein the liposome comprises a lipid with a cationic head group and a lipid with a zwitterionic head group, and wherein the liposome is formed from a mixture of lipids, wherein the proportion of those lipids which are PEGylated is less than 10 mol% of the total amount of lipids, and wherein the remainder is made of 35-50 mol% cholesterol, 30-70 mol% cationic lipid and 5-15 mol% DSPC; optionally wherein the process is for preparing a liposome according to any of claims 2-6.

*Claims not shown above remain as granted (subject to renumbering of claims and of cross-referenced claims).*

Annex F

**EP 856 – Amendment B**

1. A liposome within which RNA encoding an immunogen of interest is encapsulated, wherein the liposome comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is between 1kDa and 3kDa; wherein the immunogen elicits an immune response against a coronavirus, and wherein the immunogen is a coronavirus spike polypeptide, wherein the liposome comprises a lipid with a cationic head group and a lipid with a zwitterionic head group, and wherein the liposome is formed from a mixture of lipids, wherein 2 mol% of the total lipid is a PEG-DMG, and wherein the remainder is made of 35-50 mol% cholesterol, 30-70 mol% cationic lipid and 5-15 mol% DSPC.

~~4. The liposome of any preceding claim, wherein the liposome comprises a lipid with a cationic head group.~~

~~5. The liposome of any preceding claim, wherein the liposome comprises a lipid with a zwitterionic head group.~~

9. A process for preparing a RNA-containing liposome, comprising a step of mixing RNA with one or more lipids, under conditions such that the lipids form a liposome in which the RNA is encapsulated, wherein at least one lipid includes a polyethylene glycol moiety which becomes located on the liposome's exterior during the process, and wherein the average molecular mass of the polyethylene glycol is between 1kDa and 3kDa; wherein the RNA encodes an immunogen which elicits an immune response against a coronavirus, and wherein the immunogen is a coronavirus spike polypeptide, wherein the liposome comprises a lipid with a cationic head group and a lipid with a zwitterionic head group, and wherein the liposome is formed from a mixture of lipids, wherein 2 mol% of the total lipid is a PEG-DMG, and wherein the remainder is made of 35-50 mol% cholesterol, 30-70 mol% cationic lipid and 5-15 mol% DSPC; optionally wherein the process is for preparing a liposome according to any of claims 2-6.

*Claims not shown above remain as granted (subject to renumbering of claims and of cross-referenced claims).*